3 products in acute respiratory diagnosis, chronic respiratory management and OSA which all have massive revenue potential, this will be doubtful. IMO, the global revenue for just SleepCheck can bring in $4M.
- Forums
- ASX - By Stock
- RAP
- Ann: Continued Use of ResAppDx at COVID-19 Respiratory Clinic
Ann: Continued Use of ResAppDx at COVID-19 Respiratory Clinic, page-58
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 175 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)